Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment

  • Amer, Fatma
  • Yousif, Monkez M
  • Hammad, Noha M
  • Garcia Cehic, Damir
  • Nieto Aponte, Leonardo
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
Resistance-associated substitutions; RAS; Subtype 4a, Sustituciones asociadas a la resistencia; RAS; Subtipo 4a, Substitucions associades a la resistència; RAS; Subtipus 4a, Purpose: To study resistance-associated substitutions using next-generation sequencing in Egyptian hepatitis C virus-infected patients failing direct-acting antiviral treatment. Methods: The current study describes three cases of treatment failure in patients referred to Zagazig Viral Hepatitis Treatment Center (ZVHTC), Sharkia Governorate, Egypt. RAS were identified and characterized using deep sequencing. The first patient had breakthrough while receiving a daclatasvir (DCV)+sofosbuvir (SOF) regimen, patient 2 relapsed after treatment with DCV+SOF+ribavirin (RBV), and patient 3 relapsed after DCV+SOF therapy. A serum sample was collected from each patient at failure and sent to Vall d’Hebron Research Institute at Hospital Universitari Vall d’Hebron in Barcelona (Spain) for deep-sequencing study to identify and characterize the RAS present in the samples. Results: The following were identified: L28M, L30S and L28M+L30S in patient 1, L30R in patient 2, and R155C, D168E, L28M, L30H, L30S, L28M+L30H, and L28M+L30S in patient 3. Conclusion: To the best of our knowledge, this is the first report from Egypt of patients failing DAA-based therapy, describing the associated RAS. This information will be of help to understand the natural history of HCV in Egyptian patients and guide the proper choice of retreatment protocols., This study was supported by the Spanish Ministry of Health, Consumer Affairs, and Social Welfare, grant name: Plan Estrategico Nacional contra la Hepatitis C. This study was also funded by Instituto de Salud Carlos III, PI15/00856 and PI16/00337, cofinanced by CIBERehd (Consorcio Centro de Investigacion en Red de Enfermedades Hepaticas y Digestivas), which is funded by Instituto de Salud Carlos III and Centro para el Desarrollo Tecnologico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number, IDI-20151125
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

  • Llorens Revull, Meritxell
  • Costafreda Salvany, Maria Isabel
  • Rico Blazquez, Angie
  • Guerrero Murillo, Mercedes
  • Soria Benito, Maria Eugenia
  • Piriz Ruzo, Sofia Romina
  • Vargas Accarino, Elena
  • Gabriel Medina, Pablo
  • Rodríguez Frias, Francisco
  • Riveiro Barciela, Maria del Mar
  • Quer Sivila, Josep
  • Esteban Mur, Juan Ignacio
Fibrosi hepàtica; Cèl·lules T; Teràpia de citocines, Fibrosis hepática; Células T; Terapia de citocinas, Liver fibrosis; T cells; Cytokine therapy, Background & aims HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. Methods We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. Results We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Conclusions Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA’s therapies., This study was funded by Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF): grant numbers PI16/00337, PI18/00210 and PI19/00301. C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121 and CPII19/00001) cofinanced by the European Regional Development Fund (ERDF).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice, Comparison with Massive Sequencing

  • Nieto, Leonardo|||0000-0002-1336-5645
  • Quer, Josep|||0000-0003-0014-084X
  • Ruiz-Ripa, Alicia
  • Tabernero, David|||0000-0002-1146-4084
  • González, Carolina|||0000-0002-0169-5874
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Vila, Marta|||0000-0001-9303-5189
  • Asensio, Miriam
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Ruiz, Gerardo
  • Chen, Qian
  • Ordeig, Laura
  • Llorens, Meritxell
  • Saez, Montserrat
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Esteban, Rafael|||0000-0001-5280-392X
  • Buti, Maria|||0000-0002-0732-3078
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
The unequivocal identification of hepatitis C virus (HCV) subtypes 1a/1b and genotypes 2 to 6 is required for optimizing the effectiveness of interferon-free, direct-acting antiviral therapies. We compared the performance of a new real-time HCV genotyping assay used on the Cobas 4800 system (C4800) with that of high-resolution HCV subtyping (HRCS). In total, 502 samples were used, including 184 samples from chronic HCV patients (from routine laboratory activity during April 2016), 5 stored samples with double HCV genotype infections for testing the limitations of the method, and 313 samples from a screening protocol implemented in our hospital (from May to August 2016) based on the new method to further determine its genotyping accuracy. A total of 282 samples, including 171 from April 2016 (the 13 remaining had too low of a viral load for HRCS), 5 selected with double infections, and 106 from screening, were analyzed by both methods, and 220 were analyzed only by the C4800. The C4800 correctly subtyped 125 of 126 1a/1b samples, and the 1 remaining sample was reported as genotype 1. The C4800 correctly genotyped 38 of 45 non-1a/1b samples (classified by HRCS), and it reported the remaining 7 samples as indeterminate. One hundred two of 106 non-1a/1b genotype samples that were identified using the C4800 for screening were confirmed by HRCS. In the 4 remaining samples, 3 were correctly reported as genotype 1 (without defining the subtype) and 1 was reported as indeterminate. None of the samples were misgenotyped. Four of 7 samples with double HCV infections were correctly genotyped by the C4800. Excluding the 5 selected double-infected samples, the C4800 showed 95.7% concordant results for genotyping HCVs 2 to 6 and 1a/1b subtyping, and 99.2% concordance for subtyping 1a/1b single infections in clinical samples. To improve laboratory workflow, we propose using the C4800 as a first-line test for HCV genotyping and 1a/1b classification, followed by transferring non-1a/1b samples to a center where HRCS is available, if further characterization is needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections, A real-life experience

  • del Campo, José A.
  • Parra-Sánchez, Manuel
  • Figueruela, Blanca
  • García-Rey, Silvia
  • Quer, Josep|||0000-0003-0014-084X
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Bernal, Samuel
  • Grande, Lourdes
  • Palomares, José C.
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
The effectiveness of the new generation of hepatitis C treatments named direct-acting antiviral agents (DAAs) depends on the genotype, subtype, and resistance-associated substitutions present in individual patients. The aim of this study was to evaluate a massive sequencing platform for the analysis of genotypes and subtypes of hepatitis C virus (HCV) in order to optimize therapy. A total of 84 patients with hepatitis C were analyzed. The routine genotyping methodology for HCV used at the study institution (Versant HCV Assay, LiPA) was compared with a deep sequencing platform (454/GS-Junior and Illumina MiSeq). The mean viral load in these HCV patients was 6.89 × 10 6 ± 7.02 × 10 5. Viral genotypes analyzed by LiPA were distributed as follows: 26% genotype 1a (22/84), 55% genotype 1b (46/84), 1% genotype 1 (1/84), 2.5% genotype 3 (2/84), 6% genotype 3a (5/84), 6% genotype 4a/c/d (5/84). When analyzed by deep sequencing, the samples were distributed as follows: 27% genotype 1a (23/84), 56% genotype 1b (47/84), 8% genotype 3a (7/84), 5% genotype 4d (4/84), 2.5% genotype 4f (2/84). Six of the 84 patients (7%) were infected with more than one subtype. Among these, 33% (2/6) failed DAA-based triple therapy. The detection of mixed infection could explain some treatment failures. Accurate determination of viral genotypes and subtypes would allow optimal patient management and improve the effectiveness of DAA therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Chen, Qian
  • Soria, Maria Eugenia
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Nieto, Leonardo|||0000-0002-1336-5645
  • Castells, Lluís|||0000-0002-6672-5931
  • Imaz, Arkaitz|||0000-0001-8411-1952
  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Domingo, Esteban
  • Buti, Maria|||0000-0002-0732-3078
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Quer, Josep|||0000-0003-0014-084X
Controversy is ongoing about whether a minority mutant present at frequencies below 15% may be clinically relevant and should be considered to guide treatment. Resistance-associated substitution (RAS) studies were performed in patients before and at failure of antiviral treatments using Next-generation hepatitis C virus (HCV) sequencing (NGS). We have found two patients with genotype 1a infection having RAS in 3.5%-7.1% of the viral population at baseline that were selected during ledipasvir + sofosbuvir treatment. Co-selection of RAS located in a region not directly affected by the antiviral treatment also occurred. This observation calls into question, the recommendations to guide RAS-based direct-acting antiviral (DAA) treatment only when RAS are present in.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evidence for positive selection of hepatitis A virus antigenic variants in vaccinated men-having-sex-with men patients, Implications for immunization policies

  • Sabrià, Aurora
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Guix, Susana|||0000-0002-1588-3198
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Manzanares-Laya, Sandra
  • Caylà, Joan A.|||0000-0003-3891-111X
  • Bosch Navarro, Albert|||0000-0002-8111-9059
  • Quer, Josep|||0000-0003-0014-084X
  • Pintó, Rosa M.|||0000-0003-1382-6648
A huge outbreak in the men-having-sex-with-men (MSM) has hit Europe during the years 2016-2018. Outbreak control has been hampered by vaccine shortages in many countries, and to minimize their impact, reduction of antigen doses has been implemented. However, these measures may have consequences on the evolution of hepatitis A virus (HAV), leading to the emergence of antigenic variants. Cases in vaccinated MSM patients have been detected in Barcelona, opening the possibility to study HAV evolution under immune pressure. We performed deep-sequencing analysis of ten overlapping fragments covering the complete capsid coding region of HAV. A total of 14578255 reads were obtained and used for the analysis of virus evolution in vaccinated versus non-vaccinated patients. We estimated maximum and minimum mutation frequencies, and Shannon entropy in the quasispecies of each patient. Non-synonymous (NSyn) mutations affecting residues exposed in the capsid surface were located, with respect to epitopes, using the recently described crystal structure of HAV, as an indication of its potential role in escaping to the effect of vaccines. HAV evolution at the quasispecies level, in non-vaccinated and vaccinated patients, revealed higher diversity in epitope-coding regions of the vaccinated group. Although amino acid replacements occurring in and around the epitopes were observed in both groups, their abundance was significantly higher in the quasispecies of vaccinated patients, indicating ongoing processes of fixation. Our data suggest positive selection of antigenic variants in some vaccinated patients, raising concerns for new vaccination polices directed to the MSM group.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

  • von Massow, Georg
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Macià, María Dolores
  • Escarda, Ana
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. During routine diagnostic, a sample from an Equatorial Guinea patient could not be classified into any of the existing subtypes. The whole genome was analyzed to confirm that the new isolate could be classified as a new HCV subtype. In addition, naturally occurring resistance-associated substitutions (RAS) were analyzed by NGS. Whole-genome analysis based on p-distances suggests that the sample belongs to a new HCV genotype 1 subtype. Several RAS in the NS3 (S122T, D168E and I170V) and NS5A protein (Q(1b)24K, R(1b)30Q and Y93L+Y93F) were found, which could limit the use of some inhibitors for treating this subtype. RAS studies of new subtypes are of great interest for tailoring treatment, as no data on treatment efficacy are reported. In our case, the patient has not yet been treated, and the RAS report will be used to design the most effective treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hepatitis C virus intrinsic molecular determinants may contribute to the development of cholestatic hepatitis after liver transplantation

  • Gambato, Martina
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Quer, Josep|||0000-0003-0014-084X
  • Koutsoudakis, George
  • González, Patricia
  • Caro-Pérez, Noelia
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • García-González, Neris
  • González-Candelas, Fernando|||0000-0002-0879-5798
  • Ignacio Esteban, Juan
  • Crespo, Gonzalo|||0000-0002-1178-4897
  • Navasa, Miquel|||0000-0002-3130-9604
  • Forns, Xavier|||0000-0002-8188-1764
  • Pérez-Del-Pulgar, Sofía
Cholestatic hepatitis C (CHC) is a severe form of hepatitis C virus (HCV) infection recurrence that leads to high graft loss rates early after liver transplantation (LT). To investigate the pathogenic mechanisms of CHC, we analysed HCV quasispecies in CHC patients compared to a control group (mild hepatitis C recurrence) by deep pyrosequencing. At the time of LT, NS5B quasispecies complexity was similar between the two groups but, after LT, it decreased more sharply in CHC patients than in the control group. Interestingly, the major variant before LT propagated efficiently and remained as the dominant sequence after LT in 62% of CHC patients versus 11% of controls (P=0.031). Sequence analysis of the complete nonstructural region in a limited number of patients revealed a potential 12 aa signature specific to the CHC group. These data suggest that intrinsic molecular determinants in the circulating HCV quasispecies may provide a fitness advantage, contributing to the development of CHC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of intra- and inter-host norovirus P2 genetic variability in linked individuals by amplicon sequencing

  • Sabrià, Aurora
  • Pintó, Rosa M.|||0000-0003-1382-6648
  • Bosch Navarro, Albert|||0000-0002-8111-9059
  • Quer, Josep|||0000-0003-0014-084X
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Domínguez, Ángela|||0000-0003-0219-1907
  • Carol Torrades, Monica
  • Sala-Farré, Maria Rosa
  • Guix, Susana|||0000-0002-1588-3198
Noroviruses are the main cause of epidemics of acute gastroenteritis at a global scale. Although chronically infected immunocompromised individuals are regarded as potential reservoirs for the emergence of new viral variants, viral quasispecies distribution and evolution patterns in acute symptomatic and asymptomatic infections has not been extensively studied. Amplicons of 450 nts from the P2 coding capsid domain were studied using next-generation sequencing (454/GS-Junior) platform. Inter-host diversity between symptomatic and asymptomatic acutely infected individuals linked to the same outbreak as well as their viral intra-host diversity over time were characterized. With an average of 2848 reads per sample and a cutoff frequency of 0.1%, minor variant haplotypes were detected in 5 out of 8 specimens. Transmitted variants could not be confirmed in all infected individuals in one outbreak. The observed initial intra-host viral diversity in asymptomatically infected subjects was higher than in symptomatic ones. Viral quasispecies evolution over time within individuals was host-specific, with an average of 2.8 nt changes per day (0.0062 changes per nucleotide per day) in a given symptomatic case. Nucleotide polymorphisms were detected in 28 out of 450 analyzed nucleotide positions, 32.14% of which were synonymous and 67.86% were non-synonymous. Most observed amino acid changes emerged at or near blockade epitopes A, B, D and E. Our results suggest that acutely infected individuals, even in the absence of symptoms, which go underreported and may enhance transmission, may contribute to norovirus genetic variability and evolution.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus

  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Chen, Qian
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Llorens, Meritxell
  • de Ávila, Ana Isabel
  • Beach, Nathan M.
  • Domingo, Esteban
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Buti, Maria|||0000-0002-0732-3078
  • Esteban, Rafael|||0000-0001-5280-392X
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
  • Perales Viejo, Celia|||0000-0003-1618-1937
Despite the high sustained virological response rates achieved with current directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5-10% of treated patients do not respond to current antiviral therapies, and basal resistance to DAAs is increasingly detected among treatment-naïve infected individuals. Identification of amino acid substitutions (including those in minority variants) associated with treatment failure requires analytical designs that take into account the high diversification of HCV in more than 86 subtypes according to the ICTV website (June 2017). The methodology has involved five sequential steps: (i) to design 280 oligonucleotide primers (some including a maximum of three degenerate positions), and of which 120 were tested to amplify NS3, NS5A-, and NS5B-coding regions in a subtype-specific manner, (ii) to define a reference sequence for each subtype, (iii) to perform experimental controls to define a cut-off value for detection of minority amino acids, (iv) to establish bioinformatics' tools to quantify amino acid replacements, and (v) to validate the procedure with patient samples. A robust ultra-deep sequencing procedure to analyze HCV circulating in serum samples from patients infected with virus that belongs to the ten most prevalent subtypes worldwide: 1a, 1b, 2a, 2b, 2c, 2j, 3a, 4d, 4e, 4f has been developed. Oligonucleotide primers are subtype-specific. A cut-off value of 1% mutant frequency has been established for individual mutations and haplotypes. The methodological pipeline described here is adequate to characterize in-depth mutant spectra of HCV populations, and it provides a tool to understand HCV diversification and treatment failures. The pipeline can be periodically extended in the event of HCV diversification into new genotypes or subtypes, and provides a framework applicable to other RNA viral pathogens, with potential to couple detection of drug-resistant mutations with treatment planning. The online version of this article (10.1186/s12879-018-3356-6) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rare haplotype load as marker for lethal mutagenesis

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Gallego, Isabel
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Domingo, Esteban
RNA viruses replicate with a template-copying fidelity, which lies close to an extinction threshold. Increases of mutation rate by nucleotide analogues can drive viruses towards extinction. This transition is the basis of an antiviral strategy termed lethal mutagenesis. We have introduced a new diversity index, the rare haplotype load (RHL), to describe NS5B (polymerase) mutant spectra of hepatitis C virus (HCV) populations passaged in absence or presence of the mutagenic agents favipiravir or ribavirin. The increase in RHL is more prominent in mutant spectra whose expansions were due to nucleotide analogues than to multiple passages in absence of mutagens. Statistical tests for paired mutagenized versus non-mutagenized samples with 14 diversity indices show that RHL provides consistently the highest standardized effect of mutagenic treatment difference for ribavirin and favipiravir. The results indicate that the enrichment of viral quasispecies in very low frequency minority genomes can serve as a robust marker for lethal mutagenesis. The diagnostic value of RHL from deep sequencing data is relevant to experimental studies on enhanced mutagenesis of viruses, and to pharmacological evaluations of inhibitors suspected to have a mutagenic activity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Costafreda Salvany, Maria Isabel|||0000-0002-3114-3034
  • Rico, Angie
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Soria, Maria Eugenia
  • Píriz-Ruzo, Sofía
  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Gabriel-Medina, Pablo|||0000-0003-3079-6364
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Quer, Josep|||0000-0003-0014-084X
  • Sauleda, Silvia|||0000-0001-7343-9557
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Bes, Marta|||0000-0001-6103-072X
HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA's therapies.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

  • Llorens Revull, Meritxell
  • Costafreda Salvany, Maria Isabel
  • Rico Blazquez, Angie
  • Guerrero Murillo, Mercedes
  • Soria Benito, Maria Eugenia
  • Piriz Ruzo, Sofia Romina
  • Vargas Accarino, Elena
  • Gabriel Medina, Pablo
  • Rodríguez Frias, Francisco
  • Riveiro Barciela, Maria del Mar
  • Quer Sivila, Josep
  • Esteban Mur, Juan Ignacio
Fibrosi hepàtica; Cèl·lules T; Teràpia de citocines, Fibrosis hepática; Células T; Terapia de citocinas, Liver fibrosis; T cells; Cytokine therapy, Background & aims HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. Methods We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. Results We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Conclusions Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA’s therapies., This study was funded by Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF): grant numbers PI16/00337, PI18/00210 and PI19/00301. C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121 and CPII19/00001) cofinanced by the European Regional Development Fund (ERDF).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment

  • Amer, Fatma
  • Yousif, Monkez M
  • Hammad, Noha M
  • Garcia Cehic, Damir
  • Nieto Aponte, Leonardo
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
Resistance-associated substitutions; RAS; Subtype 4a, Sustituciones asociadas a la resistencia; RAS; Subtipo 4a, Substitucions associades a la resistència; RAS; Subtipus 4a, Purpose: To study resistance-associated substitutions using next-generation sequencing in Egyptian hepatitis C virus-infected patients failing direct-acting antiviral treatment. Methods: The current study describes three cases of treatment failure in patients referred to Zagazig Viral Hepatitis Treatment Center (ZVHTC), Sharkia Governorate, Egypt. RAS were identified and characterized using deep sequencing. The first patient had breakthrough while receiving a daclatasvir (DCV)+sofosbuvir (SOF) regimen, patient 2 relapsed after treatment with DCV+SOF+ribavirin (RBV), and patient 3 relapsed after DCV+SOF therapy. A serum sample was collected from each patient at failure and sent to Vall d’Hebron Research Institute at Hospital Universitari Vall d’Hebron in Barcelona (Spain) for deep-sequencing study to identify and characterize the RAS present in the samples. Results: The following were identified: L28M, L30S and L28M+L30S in patient 1, L30R in patient 2, and R155C, D168E, L28M, L30H, L30S, L28M+L30H, and L28M+L30S in patient 3. Conclusion: To the best of our knowledge, this is the first report from Egypt of patients failing DAA-based therapy, describing the associated RAS. This information will be of help to understand the natural history of HCV in Egyptian patients and guide the proper choice of retreatment protocols., This study was supported by the Spanish Ministry of Health, Consumer Affairs, and Social Welfare, grant name: Plan Estrategico Nacional contra la Hepatitis C. This study was also funded by Instituto de Salud Carlos III, PI15/00856 and PI16/00337, cofinanced by CIBERehd (Consorcio Centro de Investigacion en Red de Enfermedades Hepaticas y Digestivas), which is funded by Instituto de Salud Carlos III and Centro para el Desarrollo Tecnologico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number, IDI-20151125